Intrinsic value of Icon - ICLR

Previous Close

$135.00

  Intrinsic Value

$89.17

stock screener

  Rating & Target

sell

-34%

Previous close

$135.00

 
Intrinsic value

$89.17

 
Up/down potential

-34%

 
Rating

sell

We calculate the intrinsic value of ICLR stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 7.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  5.50
  5.45
  5.40
  5.36
  5.33
  5.30
  5.27
  5.24
  5.22
  5.19
  5.17
  5.16
  5.14
  5.13
  5.11
  5.10
  5.09
  5.08
  5.08
  5.07
  5.06
  5.05
  5.05
  5.04
  5.04
  5.04
  5.03
  5.03
  5.03
  5.02
Revenue, $m
  1,855
  1,956
  2,062
  2,173
  2,288
  2,410
  2,536
  2,669
  2,809
  2,954
  3,107
  3,267
  3,435
  3,612
  3,796
  3,990
  4,193
  4,406
  4,630
  4,865
  5,111
  5,369
  5,640
  5,925
  6,223
  6,537
  6,866
  7,211
  7,574
  7,954
Variable operating expenses, $m
  1,320
  1,387
  1,458
  1,531
  1,609
  1,689
  1,774
  1,862
  1,955
  2,052
  2,070
  2,177
  2,289
  2,406
  2,529
  2,658
  2,794
  2,936
  3,084
  3,241
  3,405
  3,577
  3,758
  3,947
  4,146
  4,355
  4,574
  4,804
  5,045
  5,299
Fixed operating expenses, $m
  174
  178
  181
  185
  190
  194
  198
  202
  207
  211
  216
  221
  226
  231
  236
  241
  246
  252
  257
  263
  268
  274
  280
  287
  293
  299
  306
  313
  320
  327
Total operating expenses, $m
  1,494
  1,565
  1,639
  1,716
  1,799
  1,883
  1,972
  2,064
  2,162
  2,263
  2,286
  2,398
  2,515
  2,637
  2,765
  2,899
  3,040
  3,188
  3,341
  3,504
  3,673
  3,851
  4,038
  4,234
  4,439
  4,654
  4,880
  5,117
  5,365
  5,626
Operating income, $m
  361
  391
  423
  456
  490
  527
  565
  605
  647
  691
  821
  870
  921
  975
  1,032
  1,091
  1,154
  1,219
  1,289
  1,361
  1,438
  1,518
  1,602
  1,691
  1,785
  1,883
  1,986
  2,094
  2,209
  2,329
EBITDA, $m
  483
  515
  549
  584
  621
  660
  700
  743
  788
  835
  885
  937
  991
  1,049
  1,109
  1,173
  1,239
  1,309
  1,383
  1,460
  1,542
  1,627
  1,717
  1,812
  1,912
  2,016
  2,126
  2,242
  2,363
  2,491
Interest expense (income), $m
  14
  19
  22
  25
  28
  31
  34
  38
  42
  46
  50
  54
  58
  63
  68
  73
  79
  84
  90
  97
  103
  110
  117
  125
  133
  141
  150
  159
  169
  179
  189
Earnings before tax, $m
  343
  370
  398
  428
  459
  492
  527
  563
  601
  641
  767
  812
  858
  907
  958
  1,012
  1,069
  1,129
  1,192
  1,258
  1,328
  1,401
  1,478
  1,558
  1,643
  1,733
  1,827
  1,926
  2,030
  2,139
Tax expense, $m
  93
  100
  107
  116
  124
  133
  142
  152
  162
  173
  207
  219
  232
  245
  259
  273
  289
  305
  322
  340
  358
  378
  399
  421
  444
  468
  493
  520
  548
  578
Net income, $m
  250
  270
  291
  312
  335
  359
  384
  411
  439
  468
  560
  592
  626
  662
  700
  739
  781
  824
  870
  918
  969
  1,023
  1,079
  1,138
  1,200
  1,265
  1,334
  1,406
  1,482
  1,562

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  2,265
  2,389
  2,518
  2,653
  2,794
  2,942
  3,097
  3,259
  3,429
  3,607
  3,794
  3,990
  4,195
  4,410
  4,635
  4,872
  5,120
  5,380
  5,653
  5,940
  6,240
  6,556
  6,887
  7,234
  7,599
  7,981
  8,383
  8,805
  9,247
  9,712
Adjusted assets (=assets-cash), $m
  2,265
  2,389
  2,518
  2,653
  2,794
  2,942
  3,097
  3,259
  3,429
  3,607
  3,794
  3,990
  4,195
  4,410
  4,635
  4,872
  5,120
  5,380
  5,653
  5,940
  6,240
  6,556
  6,887
  7,234
  7,599
  7,981
  8,383
  8,805
  9,247
  9,712
Revenue / Adjusted assets
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
  0.819
Average production assets, $m
  564
  595
  627
  660
  696
  733
  771
  811
  854
  898
  945
  993
  1,044
  1,098
  1,154
  1,213
  1,275
  1,340
  1,408
  1,479
  1,554
  1,632
  1,715
  1,801
  1,892
  1,987
  2,087
  2,192
  2,302
  2,418
Working capital, $m
  184
  194
  204
  215
  227
  239
  251
  264
  278
  292
  308
  323
  340
  358
  376
  395
  415
  436
  458
  482
  506
  532
  558
  587
  616
  647
  680
  714
  750
  787
Total debt, $m
  401
  456
  514
  574
  637
  702
  771
  844
  919
  999
  1,082
  1,169
  1,260
  1,356
  1,456
  1,561
  1,672
  1,787
  1,909
  2,036
  2,170
  2,311
  2,458
  2,612
  2,775
  2,945
  3,124
  3,311
  3,508
  3,715
Total liabilities, $m
  1,008
  1,063
  1,120
  1,180
  1,243
  1,309
  1,378
  1,450
  1,526
  1,605
  1,688
  1,775
  1,867
  1,962
  2,063
  2,168
  2,278
  2,394
  2,516
  2,643
  2,777
  2,917
  3,065
  3,219
  3,381
  3,552
  3,730
  3,918
  4,115
  4,322
Total equity, $m
  1,257
  1,326
  1,397
  1,472
  1,551
  1,633
  1,719
  1,809
  1,903
  2,002
  2,106
  2,214
  2,328
  2,447
  2,573
  2,704
  2,842
  2,986
  3,138
  3,297
  3,463
  3,638
  3,822
  4,015
  4,217
  4,430
  4,653
  4,887
  5,132
  5,390
Total liabilities and equity, $m
  2,265
  2,389
  2,517
  2,652
  2,794
  2,942
  3,097
  3,259
  3,429
  3,607
  3,794
  3,989
  4,195
  4,409
  4,636
  4,872
  5,120
  5,380
  5,654
  5,940
  6,240
  6,555
  6,887
  7,234
  7,598
  7,982
  8,383
  8,805
  9,247
  9,712
Debt-to-equity ratio
  0.320
  0.340
  0.370
  0.390
  0.410
  0.430
  0.450
  0.470
  0.480
  0.500
  0.510
  0.530
  0.540
  0.550
  0.570
  0.580
  0.590
  0.600
  0.610
  0.620
  0.630
  0.640
  0.640
  0.650
  0.660
  0.660
  0.670
  0.680
  0.680
  0.690
Adjusted equity ratio
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555
  0.555

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  250
  270
  291
  312
  335
  359
  384
  411
  439
  468
  560
  592
  626
  662
  700
  739
  781
  824
  870
  918
  969
  1,023
  1,079
  1,138
  1,200
  1,265
  1,334
  1,406
  1,482
  1,562
Depreciation, amort., depletion, $m
  122
  124
  126
  128
  131
  133
  136
  139
  141
  144
  63
  67
  70
  74
  77
  81
  86
  90
  94
  99
  104
  110
  115
  121
  127
  133
  140
  147
  155
  162
Funds from operations, $m
  372
  394
  417
  441
  466
  493
  520
  550
  580
  612
  624
  659
  697
  736
  777
  821
  866
  914
  965
  1,018
  1,073
  1,132
  1,194
  1,259
  1,327
  1,398
  1,474
  1,553
  1,636
  1,724
Change in working capital, $m
  10
  10
  10
  11
  11
  12
  13
  13
  14
  14
  15
  16
  17
  17
  18
  19
  20
  21
  22
  23
  24
  26
  27
  28
  30
  31
  33
  34
  36
  38
Cash from operations, $m
  362
  384
  406
  430
  455
  481
  508
  536
  566
  598
  608
  643
  680
  718
  759
  801
  846
  893
  942
  994
  1,049
  1,106
  1,167
  1,230
  1,297
  1,367
  1,441
  1,519
  1,600
  1,686
Maintenance CAPEX, $m
  -36
  -38
  -40
  -42
  -44
  -47
  -49
  -52
  -54
  -57
  -60
  -63
  -67
  -70
  -74
  -77
  -81
  -86
  -90
  -94
  -99
  -104
  -110
  -115
  -121
  -127
  -133
  -140
  -147
  -155
New CAPEX, $m
  -30
  -31
  -32
  -34
  -35
  -37
  -39
  -40
  -42
  -44
  -46
  -49
  -51
  -54
  -56
  -59
  -62
  -65
  -68
  -71
  -75
  -79
  -82
  -86
  -91
  -95
  -100
  -105
  -110
  -116
Cash from investing activities, $m
  -66
  -69
  -72
  -76
  -79
  -84
  -88
  -92
  -96
  -101
  -106
  -112
  -118
  -124
  -130
  -136
  -143
  -151
  -158
  -165
  -174
  -183
  -192
  -201
  -212
  -222
  -233
  -245
  -257
  -271
Free cash flow, $m
  297
  315
  334
  354
  375
  397
  420
  444
  470
  496
  502
  531
  562
  595
  629
  665
  703
  743
  785
  829
  875
  924
  975
  1,029
  1,085
  1,145
  1,208
  1,274
  1,343
  1,416
Issuance/(repayment) of debt, $m
  52
  55
  57
  60
  63
  66
  69
  72
  76
  79
  83
  87
  91
  96
  100
  105
  110
  116
  122
  127
  134
  140
  147
  155
  162
  170
  179
  188
  197
  207
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  52
  55
  57
  60
  63
  66
  69
  72
  76
  79
  83
  87
  91
  96
  100
  105
  110
  116
  122
  127
  134
  140
  147
  155
  162
  170
  179
  188
  197
  207
Total cash flow (excl. dividends), $m
  349
  370
  392
  414
  438
  463
  489
  516
  545
  576
  585
  618
  653
  690
  729
  770
  813
  859
  906
  956
  1,009
  1,064
  1,122
  1,183
  1,248
  1,315
  1,387
  1,461
  1,540
  1,623
Retained Cash Flow (-), $m
  -66
  -69
  -72
  -75
  -78
  -82
  -86
  -90
  -94
  -99
  -104
  -109
  -114
  -119
  -125
  -131
  -138
  -144
  -152
  -159
  -167
  -175
  -184
  -193
  -202
  -212
  -223
  -234
  -246
  -258
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  283
  302
  320
  339
  360
  381
  403
  426
  451
  477
  481
  510
  540
  571
  604
  639
  676
  714
  755
  797
  842
  889
  939
  991
  1,045
  1,103
  1,164
  1,227
  1,294
  1,365
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  272
  276
  279
  279
  279
  276
  272
  266
  259
  250
  228
  217
  205
  192
  177
  162
  147
  132
  116
  101
  87
  74
  62
  50
  41
  32
  25
  19
  14
  10
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

FINANCIAL RATIOS  of  Icon (ICLR)

Valuation Ratios
P/E Ratio 28.1
Price to Sales 4.4
Price to Book 7.8
Price to Tangible Book
Price to Cash Flow 28.4
Price to Free Cash Flow 34.1
Growth Rates
Sales Growth Rate 5.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -14%
Cap. Spend. - 3 Yr. Gr. Rate 8.2%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 36.9%
Total Debt to Equity 36.9%
Interest Coverage 22
Management Effectiveness
Return On Assets 15.5%
Ret/ On Assets - 3 Yr. Avg. 14%
Return On Total Capital 21.8%
Ret/ On T. Cap. - 3 Yr. Avg. 21.2%
Return On Equity 30.7%
Return On Equity - 3 Yr. Avg. 25.7%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 42.3%
Gross Margin - 3 Yr. Avg. 41.5%
EBITDA Margin 22.4%
EBITDA Margin - 3 Yr. Avg. 20.3%
Operating Margin 18.7%
Oper. Margin - 3 Yr. Avg. 16.7%
Pre-Tax Margin 18%
Pre-Tax Margin - 3 Yr. Avg. 16.4%
Net Profit Margin 15.7%
Net Profit Margin - 3 Yr. Avg. 14.1%
Effective Tax Rate 12.7%
Eff/ Tax Rate - 3 Yr. Avg. 14%
Payout Ratio 0%

ICLR stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ICLR stock intrinsic value calculation we used $1758.439 million for the last fiscal year's total revenue generated by Icon. The default revenue input number comes from 0001 income statement of Icon. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ICLR stock valuation model: a) initial revenue growth rate of 5.5% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ICLR is calculated based on our internal credit rating of Icon, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Icon.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ICLR stock the variable cost ratio is equal to 71.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $170 million in the base year in the intrinsic value calculation for ICLR stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Icon.

Corporate tax rate of 27% is the nominal tax rate for Icon. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ICLR stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ICLR are equal to 30.4%.

Life of production assets of 14.9 years is the average useful life of capital assets used in Icon operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ICLR is equal to 9.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1191 million for Icon - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 54.082 million for Icon is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Icon at the current share price and the inputted number of shares is $7.3 billion.

RELATED COMPANIES Price Int.Val. Rating
PRAH PRA Health Sci 101.46 240.26  str.buy
MEDP Medpace Holdin 55.42 2,263.92  str.buy
LH Laboratory of 164.30 231.36  buy
MDSO Medidata Solut 70.94 19.34  str.sell
IBM International 121.44 191.80  buy

COMPANY NEWS

▶ Icon PLC (ICLR) Q3 Earnings Match Estimates   [Oct-24-18 05:55PM  Zacks]
▶ Icon PLC: 3Q Earnings Snapshot   [04:55PM  Associated Press]
▶ ICON Reports Third Quarter 2018 Results   [04:15PM  Business Wire]
▶ This Highly Rated Medical-Research Stock Topped Quarterly Views   [Oct-22-18 04:40PM  Investor's Business Daily]
▶ ICON Announces Release of ADDPLAN┬« neo   [Oct-01-18 07:00AM  Business Wire]
▶ ICON Confirms Retirement of Co-Founder Dr. Ronan Lambe   [Jul-27-18 06:00AM  Business Wire]
▶ Icon PLC: 2Q Earnings Snapshot   [Jul-25-18 06:44PM  Associated Press]
▶ ICON Reports Second Quarter 2018 Results   [04:15PM  Business Wire]
▶ Icon PLC: 1Q Earnings Snapshot   [May-02-18 06:57PM  Associated Press]
▶ ICON Reports First Quarter 2018 Results   [04:15PM  Business Wire]
▶ Edited Transcript of ICLR presentation 8-Mar-17 3:25pm GMT   [Apr-10-18 11:20AM  Thomson Reuters StreetEvents]
▶ Is It Time To Buy ICON Public Limited Company (NASDAQ:ICLR)?   [Feb-20-18 09:25AM  Simply Wall St.]
▶ Icon PLC beats 4Q profit forecasts   [06:20AM  Associated Press]
▶ ICON plc Value Analysis (NASDAQ:ICLR) : December 1, 2017   [Dec-01-17 10:56AM  Capital Cube]
▶ ETFs with exposure to ICON plc : November 13, 2017   [Nov-13-17 12:33PM  Capital Cube]
▶ ETFs with exposure to ICON plc : November 2, 2017   [Nov-02-17 12:15PM  Capital Cube]
▶ Icon PLC beats Street 3Q forecasts   [Oct-26-17 06:35AM  Associated Press]
▶ ICON Reports Third Quarter 2017 Results   [06:00AM  Business Wire]
▶ Stocks To Watch Ahead Of Earnings: PRA Health Sciences   [Oct-11-17 03:00AM  Investor's Business Daily]
▶ ETFs with exposure to ICON plc : August 23, 2017   [Aug-23-17 04:27PM  Capital Cube]
▶ Icon PLC tops Street 2Q forecasts   [Jul-27-17 10:33PM  Associated Press]
▶ ICON Acquires Mapi Group   [06:05AM  Business Wire]
▶ ICON Reports Second Quarter 2017 Results   [06:00AM  Business Wire]
▶ Historically Strong Stocks in June   [May-31-17 01:00PM  Investopedia]
▶ Which Stocks Are Showing Rising Relative Strength?   [May-30-17 03:30PM  Investor's Business Daily]
▶ ETFs with exposure to ICON Plc : May 22, 2017   [May-22-17 01:46PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.